Vivos Therapeutics Operating Expenses 2020-2024 | VVOS

Vivos Therapeutics operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Vivos Therapeutics Operating Expenses 2020-2024 | VVOS

Vivos Therapeutics operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.3B
Takeda Pharmaceutical (TAK)$46.3B
Merck (MKGAF)$22.8B
Astellas Pharma (ALPMY)$21.5B
Sandoz Group AG (SDZNY)$18B
United Therapeutics (UTHR)$16B
Summit Therapeutics (SMMT)$15.1B
Shionogi (SGIOY)$13.2B
Neurocrine Biosciences (NBIX)$11.6B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$8B
Revolution Medicines (RVMD)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$4.6B
Corcept Therapeutics (CORT)$4.6B
Crinetics Pharmaceuticals (CRNX)$4.1B
Dyne Therapeutics (DYN)$3.4B
PTC Therapeutics (PTCT)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Catalyst Pharmaceuticals (CPRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Ardelyx (ARDX)$1.6B
Harrow (HROW)$1.6B